Recurrent aberrant activation of RAS-MAPK signaling in mature B cell neoplasms, frequently associated with disease progression and drug resistance, has encouraged exploration of the efficacy of RAS/RAF/MEK/ERK inhibitors in many of these diseases. The gene discussed is RAF1; the disease is B-cell neoplasm.